Company profile
LEXICON PHARMACEUTICALS, INC.
NASDAQ:LXRXBiotechnology: Pharmaceutical Preparations
Drug pipeline (4)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| SOTAGLIFLOZIN | approved | — | 28 | approved |
| Pilavapadin | phase2 | — | 3 | no active trials |
| LX-7101 | phase1_2 | — | 1 | no active trials |
| LX-2931 | phase1 | — | 1 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (61)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06203002 | phase2 | completed | 2023-11-29 | 2025-01-14 | Lexicon Pharmaceuticals | A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP) |
| NCT01494233 | phase2 | completed | 2012-02-01 | 2013-09-01 | Lexicon Pharmaceuticals | A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome |
| NCT02147808 | phase1 | completed | 2014-05-01 | 2014-08-01 | Lexicon Pharmaceuticals | A Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Midazolam in Healthy Subjects |
| NCT03302845 | phase1 | completed | 2017-09-21 | 2017-10-23 | Lexicon Pharmaceuticals | A Phase 1 Study to Evaluate the Effects of Omeprazole and Famotidine on the Absorption of Telotristat Ethyl in Healthy Subjects |
| NCT02531035 | phase3 | completed | 2015-09-01 | 2017-04-01 | Lexicon Pharmaceuticals | A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy Alone |
FDA applications (1)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| NDA 216203 | NDA | LEXICON PHARMACEUTICALS INC | ||||
Loading… | ||||||